MedTrace Logo

Cutaneous Lupus Medication Experience Study

NCT02176148 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 11

Last updated 2025-04-24

No results posted yet for this study

Summary

Cutaneous lupus is a chronic, relapsing, auto-immune skin disease that can have many presentations. Its effect on physical appearance greatly affects patients' quality of life. In addition, 10% of patients with cutaneous lupus will develop systemic lupus. Topical therapies are the mainstay of cutaneous lupus treatment; however patients often find these treatments to be messy, inconvenient, or ineffective. In addition, for more severe disease patients are often placed on concurrent systemic therapies. The primary hypothesis of our study is that poor adherence contributes to poor treatment outcomes in patients with cutaneous lupus.

Conditions

  • Cutaneous Lupus

Interventions

DRUG

fluocinonide 0.05% cream

Sponsors & Collaborators

  • Wake Forest University Health Sciences

    lead OTHER

Principal Investigators

  • William W Huang, MD, MPH, FAAD · Wake Forest University Health Sciences

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2020-12-04
Completion
2020-12-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02176148 on ClinicalTrials.gov